Los Angeles Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Los Angeles Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-76,725	Closed	-$233K	–	1263
2024 Q4	$233K	Sell	76,725 -13,100	-15%	-$57.1K	﹤0.01%	1011
2024 Q3	$466K	Sell	89,825 -26,543	-23%	-$132K	﹤0.01%	879
2024 Q2	$299K	Buy	116,368 +23,450	+25%	+$80.1K	﹤0.01%	1016
2024 Q1	$457K	Buy	+92,918	New	+$550K	﹤0.01%	898
2023 Q4	–	Sell	-18,976	Closed	-$218K	–	1263
2023 Q3	$218K	Buy	18,976 +10,446	+122%	+$201K	﹤0.01%	1051
2023 Q2	$216K	Buy	+8,530	New	+$266K	﹤0.01%	1104
2019 Q2	–	Sell	-16,759	Closed	-$264K	–	1447
2019 Q1	$264K	Sell	16,759 -27,331	-62%	-$474K	﹤0.01%	1232
2018 Q4	$888K	Sell	44,090 -520	-1%	-$11.5K	0.01%	776
2018 Q3	$1.11M	Buy	44,610 +1,710	+4%	+$46.5K	0.01%	836
2018 Q2	$1.18M	Buy	+42,900	New	+$1.29M	0.01%	845

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Los Angeles Capital Management's RVNC Position: Q1 2025 in Review

Los Angeles Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 76,725 shares — an estimated $233K sold.

Los Angeles Capital Management first reported a position in RVNC in Q2 2018 and held it in 10 quarters. The position peaked at $1.18M in Q2 2018. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Los Angeles Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Los Angeles Capital Management sold 76,725 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $233K.
Los Angeles Capital Management first reported a position in Revance Therapeutics, Inc. in Q2 2018 and held it in 10 quarters.
Los Angeles Capital Management's Revance Therapeutics, Inc. position peaked at $1.18M in Q2 2018.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Los Angeles Capital Management's 13F filing for Q1 2025, filed 5 May 2025.